Hepatosplenic T-cell Lymphoma: Recent Progress and Future Considerations
Researchers reviewed the clinical/pathologic aspects of HSTCL and summarized the latest molecular studies and potential novel therapeutic targets.
Hematologic Cancer
HEMATOLOGIC CANCER ADVISOR
FEATURED CONTENT
-
-
Targeted Molecular Therapies for the Treatment of Chronic Lymphocytic Leukemia
Researchers reviewed promising advances in therapy options for patients with CLL and the challenges associated with these new treatments. -
Phase 1 Trial Featuring First shRNA-Edited CAR-T Therapy to Begin
FDA approves allogenic CAR T cells targeted at BCMA for phase 1 trial in relapsed/refractory multiple myeloma. -
Targeted Therapy for Non-Hodgkin Lymphoma: Current Progress and Future Plans
Novel immunotherapies and small molecule pathway inhibitors are transforming the standard of care for some of the most challenging lymphoma subtypes. -
Clonal Hematopoiesis in Hematologic Malignancies, Bone Marrow Failure Syndromes, and Stem Cell Clones
Recent studies have better elucidated the link between clonal hematopoiesis and hematologic malignancies.
HEMATOLOGIC CANCER NEWS
Recall of Specific Types of Breast Implants and Tissue Expanders Has Far-Reaching Impact on Patients With Breast Cancer
Rivaroxaban May Be a Suitable Alternative to Low-Molecular Weight Heparin in Cancer-Associated Thrombosis
Venetoclax With a Hypomethylating Agent Effective in Treatment-Naive or Relapsed/Refractory Acute Myeloid Leukemia
Uncommon Mutation in CLL Associated With More Favorable Prognostic Factors
Eltrombopag: Noninferior to Intravenous Immunoglobulin in Immune Thrombocytopenia?
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Hematologic Cancers
